Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 2.2/5
Remegen (9995 HK)
Watchlist
Contact IR
209
Analysis
Health Care
•
China
RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Remegen
•
01 Nov 2024 10:46
•
Broker
RemeGen (9995 HK) - Strong Sales in Q3, with a Narrowed Net Loss
In 3Q24, RemeGen achieved robust product sales, with revenue reaching a record high of RMB467mn (+14% QoQ, +35% YoY), driven by product sales of...
CMB International
Follow
155 Views
Share
bullish
•
Remegen
•
18 Sep 2024 07:01
Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China
RemeGen (9995 HK) is a leading biotech company committed to the discovery, development, and commercialization of innovative biologic drugs. Learn...
Smartkarma Research
Follow
9.4k Views
Share
bullish
•
Remegen
•
19 Aug 2024 21:52
•
Broker
RemeGen (9995 HK) - Strong Sales Performance in 2Q
In 2Q24, RemeGen recorded strong product sales, with revenue reaching RMB411mn (+77% YoY), mainly from the product sales of RC18 and RC48
CMB International
Follow
193 Views
Share
bearish
•
Remegen
•
14 Jul 2024 01:26
China Healthcare Weekly (July.14) - CXO's Disputed Business Model, Remegen Shares Plunged, Kelun Bio
China CXOs prioritize investment over R&D, leading to potential conflicts of interest. Investors challenged RemeGen due to poor outlook. After...
Xinyao (Criss) Wang
Follow
422 Views
Share
bullish
•
Remegen
•
02 Apr 2024 12:08
•
Broker
RemeGen (9995 HK) - Awaiting the Fruition of Overseas BD Collaborations
RemeGen recorded RMB1.08bn of revenue in FY23, including RMB1.05bn from product sales (+42% YoY), contributed equally by RC18 and RC48.
CMB International
Follow
284 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.45.1
x